SEP 1 9 2002 SE

File Copy ATTACK TO Paper # 5

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required espond to a collection of information unless it contains a valid OMB control number.

Substitute	e for form 1449A/PTO			Complete if Known		
				Application Number	09/884,875	
	INFORMATION DISCI	LOSU	RE	Filing Date	June 18, 2001	
	STATEMENT BY APP	LICA	NT	First Named Inventor	CHEN, LIN-FENG	
				Group Art Unit	4 632 /636	
	(use as many sheets as ne	cessary)	Examiner Name	To-Be Assigned Leffers	
Sheet	1	of	3	Attomey Docket Number	UCAL-234	

			U.S. PATENT DOCU	MENTS	
Examin er Initials'	Cite No. ¹	U.S. Patent Documents Number Kind Code (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant
100		5,804,374	Baltimore, et al.	09-08-1998	RECEIVED
Abol		6,150,090	Baltimore, et al.	11-21-2000	052 1 1 2022
1000		6,410,516	Baltimore, et al.	06-25-2002	SEP 1 1 2002

			F	OREIGN PATENT DOCUME	NTS	TECH CENTER 160	0/2900
Examiner Initials'	Cite No. ¹	Foreign Patent D Office ³ Number ⁴	Nocuments Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
AND		BALDWIN. "The NF- _K B and I _K B proteins: New discoveries and insights", <i>Annu. Rev. Immunol.</i> (1996) Vol. 14: 649-683.	
		√BIRD. "Activation of nuclear transcription factor NF- _k B by interleukin-1 is accompanied by casein kinase II-mediated phosphorylation of the p65 subunit", <i>J. Biol. Chem.</i> , (1997) Vol. 272: 32606-32612.	
		^V BOYES, et al. Regulation of activity of the transcription factor GATA-1 by acetylation", <i>Nature</i> , (1998) Vol. 396: 594-598.	
		√CHAKRAVARTI, et al. "A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity", Cell, (1999) Vol. 96: 393-403.	
		¹ CRESS, et al. "Histone deacetylases, transcriptional control, and cancer", <i>J. Cell Physiol.</i> , (2000) Vol. 184: 1-16.	
		*DELOUKAS, et al. "Genomic organization of the gene encoding the p65 subunit of NF-κB: Multiple variants of the p65 protein may be generated by alternative splicing", <i>Hum. Mol. Genet.</i> , (1993) Vol. 2: 1895-1900.	
Stol		GERRITSEN, et al. "CREB-binding protein/p300 are transcriptional coactivators of p65", <i>Proc. Natl. Acad. Sci. USA</i> , (1997) Vol. 94: 2927-2932.	

Examiner Signature	Swald & helpels	Date Considered 11/17/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

+

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to re respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTO				Complete if Known	BECEIVED
				Application Number	09/884,875	THEOLIVED
	INFORMATION DISCL	.os	URE	Filing Date	June 18, 2001	
	STATEMENT BY APP	LIC	ANT	First Named Inventor	CHEN, LIN-FENG	SEP 1 1 2002
				Group Art Unit	1632 /636	\mathcal{M}_{0}
	(use as many sheets as neo	essa	ny)	Examiner Name	To Be Assigned 😜	- CHT-CT - AND AND
Sheet	2	of	3	Attorney Docket Number	UCAL-234	CH CENTER 1600/29(

AAJ	GHOSH, et al. NF- _k B and rel proteins: Evolutionarily conserved mediators of immune responses", <i>Annu. Rev. Immunol.</i> , (1998) Vol. 16: 225-260.								
,	VHAMAMORI, et al. "Regulation of histone acetyltransferases p300 and PCAF by the bHLH protein twist and adenoviral oncoprotein E1A", Cell, (1999) Vol. 96: 405-413.								
	HOTTIGER. "Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300", <i>EMBO J.</i> , (1998) Vol. 17: 3124-3134.								
	IMHOF, et al. "Transcription: Gene control by targeted histone acetylation", Curr. Biol., (1998) Vol. 8: 422-424.								
	JACOBS, et al. "Structure of an I-kappa-B-alpha/NF-κB complex", <i>Cell</i> , (1998) Vol. 95(6): 749-758.								
	VKARIN. How NF- _k B is activated: The role of the I- _k B kinase (IKK) complex", <i>Oncogene</i> , (1999) Vol. 18: 6867-6874.								
	KOUZARIDES. "Acetylation: A regulatory modification to rival phosphorylation?", <i>EMBO J.</i> , (2000) Vol. 19: 1176-1179.								
	√KRAUS, et al. "Biochemical analysis of distinct activation functions in p300 that enhance transcription initiation with chromatin templates", <i>Mol. Cell. Bio.</i> , (1999) Vol. 19: 8123-8135.								
	KUO, et al. "Roles of histone acetyltransferases and deacetylases in gene regulation", Bioessays, (1998) Vol. 20: 615-626.								
	^γ LYLE, et al. "An alternatively spliced transcript, p65 delta 2, of the gene encoding the p5 subunit of the transcription factor NF-κΒ", <i>Gene</i> , (1994) Vol. 138: 265-266.								
	MADGE, et al. "A phosphatidylinositol 3-kinase/Akt pathway, activated by tumor necrosis factor or interleukin-1, inhibits apoptosis but does not activate NF- _k B in human endothelial cells", <i>J. Biol. Chem.</i> , (2000) Vol. 275: 15458-15465. ▶								
	MARTÍNEZ-BALBÁS, et al. "Regulation of E2F1 activity by acetylation", Embo. J., (2000) Vol. 19: 662-671.								
	^γ MAY, et al. "Rel/NF- _κ B and I- _κ B proteins: An overview", <i>Sem. Cancer Biol.</i> , (1997) Vol. 8: 63-73.								
	MAY, et al. "Signal transduction through NF- _k B", <i>Immunol. Today</i> , (1998) Vol. 19(2): 80-								
	NG, et al. "Histone deacetylases: Silencers for hire", TIBS, (2000) Vol. 25: 121-126.								
	PERKINS, et al. "Regulation of NF- _k B by cyclin-dependent kinases associated with the p300 coactivator", Science, (1997) Vol. 275: 523-527.								
7002	√RUBEN, et al. "Isolation of a <i>rel</i> -related human cDNA that potentially encodes the 65-kD subunit of NF-κB", <i>Science</i> , (1991) Vol. 251: 1490-1493.								

Examiner Signature	Steredd A. Weller L.	Date Considered 11-17-02

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			C	Complete if Kn wn	RECEIVED
INCODMATION DIOC.			Application Number	09/884,875	UECFIARD
INFORMATION DISCLO			Filing Date	June 18, 2001	
STATEMENT BY APPL	ICA	NT	First Named Inventor	CHEN, LIN-FENG	SEP 1 1 2000
			Group Art Unit	JB32 1636	SEP 1 1 2001
(use as many sheets as nece	ssary)	Examiner Name	To Be Assigned	effere
Sheet 3	of	3	Attorney Docket Number	UCAL-234	ECH CENTER 1600/200

ARZ	RUNDLETT, et al. "HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription", <i>Proc. Natl. Acad. Sci. USA</i> , (1996) Vol. 93: 14503-14508.						
	SEN, et al. "Multiple nuclear factors interact with the immunoglobulin enhancer sequences", Cell, (1986) Vol. 46: 705-716.						
	JSAKURAI. "I- _k B kinases phosphorylate NF- _k B p65 subunit on serine 536 in the transactivation domain", <i>J. Biol. Chem.</i> , (1999) Vol. 274: 30353-30356.						
	JSHEPPARD, et al. "Transcriptional activation by NF- _k B requires multiple coactivators", – Mol. Cell. Biol., (1999) Vol. 19: 6367-6378.						
	STERNER, et al. "Acetylation of histones and transcription-related factors", <i>Microbiol. Mol. Biol. Rev.</i> , (2000) Vol. 64: 435-459.						
	VSUN, et al. "NF- _κ B controls expression of inhibitor I- _κ Bα. Evidence for an inducible autoregulatory pathway", <i>Science</i> , (1993) Vol. 259: 1912-1915.						
	▼TAUNTON, et al. "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p", Science, (1996) Vol. 272: 408-411.						
	WANG. "Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser ²⁵⁹ is controlled by casein kinase II", <i>J. Biol. Chem.</i> , (2000) Vol. 275: 32592-32597.						
	/YOSHIDA, et al. "Trichostatin and leptomycin: Inhibition of histone deactylation and signal-dependent nuclear export", <i>Ann N.Y. Acad. Sci.</i> , (1999) Vol. 886: 23-36.						
202	ZHONG, et al. "Phosphorylation of NF- _k B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300", <i>Mol. Cell</i> , (1998) Vol. 1: 661-671.						

BEST AVAILABLE COPY

Examiner Signature	Awald & rely	Date Considered /// 7/02	
*EXAMINER:	Initial if reference considered, whether or not station is in conformance with MPE	P 609. Draw line through citation if not in conform	nance and not

considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.